Online Now: Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients – COVIDOUT study dlvr.it/SPGqc2

#Impfungen gegen #COVID19 wirken bei #Krebs|erkrankten unterschiedlich. Ambulant behandelte Patient:innen unter bestimmten Antitumor-Therapien haben besonders unzureichende Impfantwort. Ergebnisse der COVIDOUT-Studie in Cancer Cell veröffentlicht: doi.org/10.1016/j.ccel…

🎊 News from #EPICOVIDEHA!! 1⃣ #COVID19 Omicron associated with a 17% mortality in 309🏥hematological patients 2⃣💉protective against critical infection 3⃣MoAB treatment effective against 🪦in patients with critical infection Full publication: shorturl.at/fktQZ

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study dlvr.it/SSGNGZ

AB-Real Study by Claudia Angela M. Fulgenzi 👩‍⚕️ Atezolizumab+bevacizumab therapy in real world 🌎 achieves reproducible safety and efficacy 💫 compared to ImBrave150 #HCC Imperial Hepatology ILCA EASLnews ESMO - Eur. Oncology OncoAlert sciencedirect.com/science/articl…

🆕#EPICOVIDEHA publication in @BloodJournal! #Breakthrough #COVID19 in #vaccinated patients with #HematologicMalignancies - Mortality rate 9%, lower than in the pre-vaccination - MoABs, alone or combined with antivirals, show a better clinical outcome ashpublications.org/blood/article-…

✨New #EPICOVIDEHA publication by Maria Stefania Infante Jon Salmanton-García and anafcruz9 published in Frontiers - Oncology B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A EHA | SWG Infections in Hematology Survey 👉frontiersin.org/articles/10.33… European Hematology Association #IDTwitter 🧵 [1/4]

💥#EPICOVIDEHA: Improved #COVID19 outcome in hem. malignancies after #4th anti-SARS-CoV-2 vaccine💉👇 journals.lww.com/hemasphere/_la… 🪦 4% mortality 🏥40% hospital - 4% ICU 💊Tx: AVs> MoABs > AVs + MoABs HemaSphere Journal (IF = 14.6) Oliver Cornely EHA | SWG Infections in Hematology European Hematology Association Martin Hoenigl🇺🇦🇦🇹

Interested to work on #LiquidBiopsy & personalized cancer care in #LiverCancer #oncology? Open positions on all levels in my group UKE Hamburg #postdocjobs #PhDposition + technician ➡️vonfeldenlab.com ESMO - Eur. Oncology ILCA EASLnews Deutsche Krebshilfe Wilhelm Sander-Stiftung

Therapy-induced senescence upregulates antigen presentation machinery and triggers anti-tumor immunity in Acute Myeloid Leukemia biorxiv.org/content/10.110…

I am thrilled to share with you our recently published paper showing that the microbiota-derived metabolite 3-IAA influences chemotherapy efficacy in #PancreaticCancer nature nature.com/articles/s4158…

The paper is summarized in Nature News & Views by Dr. Florencia McAllister MD Anderson Cancer Center nature.com/articles/d4158…

Passive #PreExposure immunization by #tixagevimab_cilgavimab in #HemOnc patients w/ #COVID19: matched-paired analysis from #EPICOVIDEHA #tixagevimab_cilgavimab patients: ⬇️🏥 ⬇️ICU Mortality: 4% vs 13% non #tixagevimab_cilgavimab 🔗link.springer.com/content/pdf/10…

Job Alter! I'm currently offering at least three PhD or Postdoc positions! We have several projects with robust preliminary data to choose from. Our primary focus will be on studying the tumor micro- and macroenvironment in the context of therapy resistance!

uke.jobs/index.php?ac=j…

Atezo-Beva is safe and efficacious in patients previously treated with another systemic therapy! 👉 our multicenter global study now out in Hepatology Communications journals.lww.com/hepcomm/fullte… Vincent Joerg Bernhard Scheiner David James Pinato 🇺🇦 Amit G Singal Lorenza Rimassa ILCA EASL Education